Botulinum neurotoxin applications in urological disorders

doi:10.1017/CBO9781139178068.034

Chapter 33 - Botulinum neurotoxin applications in urological disorders

Published online by Cambridge University Press: 05 February 2014

Brigitte Schurch and

Edited by

Mark Hallett and

Brigitte Schurch: Affiliation:
Department of Clinical Neuroscience, Service of Neuropsychology and Neurorehabilitation, Lausanne University Hospital, Lausanne, Switzerland
Stefano Carda: Affiliation:
Department of Clinical Neuroscience Service of Neuropsychology and Neurorehabilitation, Lausanne University Hospital, Lausanne, Switzerland
Daniel Truong: Affiliation:
The Parkinson’s and Movement Disorders Institute, Fountain Valley, California
Dirk Dressler: Affiliation:
Department of Neurology, Hannover University Medical School
Mark Hallett: Affiliation:
George Washington University School of Medicine and Health Sciences, Washington, DC
Christopher Zachary: Affiliation:
Department of Dermatology, University of California, Irvine

Book contents

Get access

Summary

Introduction

Botulinum neurotoxin (BoNT) is licensed for the treatment of a number of conditions characterized by striated muscle spasticity. However, in recent years, their unlicensed use in the treatment of lower urinary tract conditions has been described (Smith et al., 2004). Chief amongst these are conditions characterized by detrusor overactivity. Treatment of vulvodynia and chronic pelvic pain, benign prostate hyperplasia (BPH) and detrusor sphincter dyssynergia (DSD) are other emerging indications with promising positive results.

Overactive bladder

The International Continence Society (ICS) report of 2002 defined overactive bladder syndrome as urgency, with or without urge incontinence, usually with frequency and nocturia, and in the absence of local pathological or hormonal factors (Abrams et al., 2002). The prevalence in Europe and USA was estimated to be 3% among men 40–44 years of age, 9% among women 40–44 years of age, 42% among men 75 years of age or older and 31% among women 75 years of age or older (Tubaro, 2004). The symptoms of overactive bladder have many potential causes and contributing factors. Urination involves the cerebral cortex, the pons, the spinal cord, the peripheral autonomic, somatic and sensory afferent innervation of the lower urinary tract and the anatomical components of the lower urinary tract itself. Disorders of any of these structures may contribute to the symptoms of overactive bladder (Fig. 33.1).

Type: Chapter
Information: Manual of Botulinum Toxin Therapy , pp. 288 - 294

DOI: https://doi.org/10.1017/CBO9781139178068.034 [Opens in a new window]

Publisher: Cambridge University Press

Print publication year: 2014

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Book purchase

Temporarily unavailable

References

Abbott, JA, Jarvis, SK, Lyons, SD, Thomson, A, Vancaille, TG (2006). Botulinum toxin type A for chronic pain and pelvic floor spasm in women: a randomized controlled trial. Obstet Gynecol, 108, 915–23.CrossRef Google Scholar PubMed

Abrams, P, Cardozo, L, Fall, M et al. (2002). The standardisation of terminology of lower urinary tract function: report from the Standardisation Subcommittee of the International Continence Society. Neurourol Urodyn, 21, 167–78.CrossRef Google Scholar

Bachmann, GA, Rosen, R (2006). Vulvodynia: a state-of-the-art consensus on definitions, diagnosis and management. J Reprod Med, 51, 447–56.Google Scholar PubMed

Bertolasi, L, Frasson, E, Cappelletti, JY et al. (2009). Botulinum neurotoxin type A injections for vaginismus secondary to vulvar vestibulitis syndrome. Obstet Gynecol, 114, 1008–16.CrossRef Google Scholar PubMed

Brin, MF, Vapnek, JM (1997). Treatment of vaginismus with botulinum toxin injections. Lancet, 349, 252–3.CrossRef Google Scholar PubMed

Brisinda, G, Cadeddu, F.Vanella, S et al. (2009). Relief by botulinum toxin of lower urinary tract symptoms owing to benign prostatic hyperplasia: early and long-term results. Urology, 73, 90–4.CrossRef Google Scholar PubMed

Chen, SL, Bih, LI, Huang, YH et al. (2008). Effect of single botulinum toxin A injection to the external urethral sphincter for treating detrusor external sphincter dyssynergia in spinal cord injury. J Rehabil Med, 40, 744–8.CrossRef Google Scholar PubMed

Chen, SL, Bih, LI, Chen, GD, Huang, YH, You, YH (2011). Comparing a transrectal ultrasound-guided with a cystoscopy-guided botulinum toxin A injection in treating detrusor external sphincter dyssynergia in spinal cord injury. Am J Phys Med Rehabil, 90, 723–30.CrossRef Google Scholar PubMed

Crawford, ED, Hirst, K, Kusek, JW et al. (2011). Effects of 100 and 300 units of onabotulinum toxin A on lower urinary tract symptoms of benign prostatic hyperplasia: a phase II randomized clinical trial. J Urol, 186, 965–70.CrossRef Google Scholar PubMed

Cruz, F, Herschorn, S, Aliotta, P et al. (2011). Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol, 60, 742–50.CrossRef Google Scholar

Dowson, C, Watkins, J, Khan, MS, Dasgupta, P, Sahai, A (2012). Repeated botulinum toxin type A injections for refractory overactive bladder: medium-term outcomes, safety profile, and discontinuation rates. Eur Urol, 61, 834–9.CrossRef Google Scholar PubMed

Duthie, JB, Vincent, M, Herbison, GP, Wilson, DI, Wilson, D (2011). Botulinum toxin injections for adults with overactive bladder syndrome. Cochrane Database Syst Rev, (12), CD005493.Google Scholar

Dykstra, DD, Presthus, J (2006). Botulinum toxin type A for the treatment of provoked vestibulodynia: an open-label, pilot study. J Reprod Med, 51, 467–70.Google Scholar

Fall, M, Baranowski, AP, Elneil, S et al. (2010). EAU guidelines on chronic pelvic pain. Eur Urol, 57, 35–48.CrossRef Google Scholar PubMed

Gallien, P, Reymann, JM, Amarenco, G et al. (2005). Placebo controlled, randomised, double blind study of the effects of botulinum A toxin on detrusor sphincter dyssynergia in multiple sclerosis patients. J Neurol Neurosurg Psychiatry, 76, 1670–6.CrossRef Google Scholar PubMed

Giannantoni, A, Mearini, E, Del Zingaro, M, Porena, M (2009). Six-year follow-up of botulinum toxin a intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results. Eur Urol, 55, 705–12.CrossRef Google Scholar PubMed

Ginsberg, D, Gousse, A, Keppenne, V et al. (2012). Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity. J Urol, 187, 2131–9.CrossRef Google Scholar PubMed

Gottsch, HP, Yang, CC, Berger, RE (2011). A pilot study of botulinum toxin A for male chronic pelvic pain syndrome. Scand J Urol Nephrol, 45, 72–6.CrossRef Google Scholar PubMed

Gunter, J, Brewer, A, Tawfik, O (2004). Botulinum toxin a for vulvodynia: a case report. J Pain, 5, 238–40.CrossRef Google Scholar PubMed

Herschorn, S, Gajewski, J, Ethans, K et al. (2011). Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial. J Urol, 185, 2229–35.CrossRef Google Scholar PubMed

Howard, FM (2003). Chronic pelvic pain. Obstet Gynecol, 101, 594–611.Google Scholar PubMed

Ikeda, Y, Zabbarova, IV, Birder, LA et al. (2012). Botulinum neurotoxin serotype A suppresses neurotransmitter release from afferent as well as efferent nerves in the urinary bladder. Eur Urol, 62, 1157–64.CrossRef Google Scholar PubMed

Jarvis, SK, Abbott, JA, Lenart, MB, Steensma, A, Vancaillie, TG (2004). Pilot study of botulinum toxin type A in the treatment of chronic pelvic pain associated with spasm of the levator ani muscles. Aust N Z J Obstet Gynaecol, 44, 46–50.CrossRef Google Scholar PubMed

Manecksha, RP, Cullen, IM, Ahmad, S et al. (2012). Prospective randomised controlled trial comparing trigone-sparing versus trigone-including intradestrusor injection of abobotulinumtoxinA for refractory idiopathic detrusor overactivity. Eur Urol, 61, 928–35.CrossRef Google Scholar PubMed

Maria, G, Brisinda, G, Civello, IM et al. (2003). Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. Urology, 62, 259–64.CrossRef Google Scholar PubMed

Meredeth, M, Karp, B, Bartrum, D, Zimmer, C, Stratton, P (2006). Botulinum toxin in the treatment of chronic pain and endometriosis. J Soc Gynecol Invest, 13, 276A.Google Scholar

Moyal-Barracco, M, Lynch, PJ (2004). 2003 ISSVD terminology and classification of vulvodynia: a historical perspective. J Reprod Med, 49, 772–7.Google Scholar PubMed

Nunns, D, Mandal, D, Byrne, M for the British Society for the Study of Vulvar Disease Guideline Group (2010). Guidelines for the management of vulvodynia. Br J Dermatol, 162, 1180–5.Google Scholar PubMed

Pelletier, F, Parratte, B, Penz, S et al. (2011). Efficacy of high doses of botulinum toxin A for treating provoked vestibulodynia. Br J Dermatol, 164, 617–22.Google Scholar PubMed

Sahai, A, Dowson, C, Khan, MS, Dasgupta, P (2010). Repeated injections of botulinum toxin-A for idiopathic detrusor overactivity. Urology, 75, 552–8.CrossRef Google Scholar PubMed

Shafik, A, El-Sibai, O (2000). Vaginismus: results of treatment with botulin toxin. J Obstet Gynaecol, 20, 300–2.Google Scholar PubMed

Silva, J, Silva, C, Saraiva, L et al. (2008). Intraprostatic botulinum toxin type A injection in patients unfit for surgery presenting with refractory urinary retention and benign prostatic enlargement. Effect on prostate volume and micturition resumption. Eur Urol, 53, 153–9.CrossRef Google Scholar PubMed

Silva, J, Pinto, R, Carvalho, T et al. (2009). Intraprostatic botulinum toxin type A injection in patients with benign prostatic enlargement: duration of the effect of a single treatment. BMC Urol, 9, 9.CrossRef Google Scholar PubMed

Smith, CP, Somogyi, GT, Boone, TB (2004). Botulinum toxin in urology: evaluation using an evidence-based medicine approach. Nat Clin Pract Urol, 1, 31–7.CrossRef Google Scholar PubMed

Thomson, AJ, Jarvis, SK, Lenart, M, Abbott, JA, Vancaillie, TG (2005). The use of botulinum toxin type A (BOTOX) as treatment for intractable chronic pelvic pain associated with spasm of the levator ani muscles. BJOG, 112, 247–9.CrossRef Google Scholar PubMed

Tubaro, A (2004). Defining overactive bladder: epidemiology and burden of disease. Urology, 64, 2–6.CrossRef Google Scholar PubMed